Search is Powered by Google
Respiratory / Asthma News

Asthma - ZaBeCor's Investigational New Drug Application Approved By The FDA

Main Category: Respiratory / Asthma
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 17 Nov 2008 - 4:00 PST

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:4 stars

4 (2 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announces today that the United States Food and Drug Administration ("FDA") has approved the Company's Investigational New Drug Application ("IND") for the treatment of asthma. This approval enables the Company to proceed with Phase I clinical trials in humans for its asthma drug candidate, Excellair(TM). The IND review included ZaBeCor's clinical development plan, Phase I clinical trial protocols, manufacturing plans and extensive pre-clinical studies.

Excellair(TM) is part of ZaBeCor's extensive intellectual property and is based upon research conducted at the University of Pennsylvania School of Medicine. Excellair(TM) focuses on applications of siRNA to the molecular protein Syk kinase. The release of biologically active mediators in many inflammatory pathways, including those operable in asthma, is initiated by Syk kinase.

"We are very pleased to have our IND approved by the FDA and we look forward to commencing Phase I clinical trials," said Alan D. Schreiber, M.D., Founder, Chairman and Chief Executive Officer of ZaBeCor. "This is an important milestone for ZaBeCor and indicates confidence in our intellectual property and data. We are delighted to continue the development of our asthma drug candidate, Excellair(TM), which we believe will be a groundbreaking treatment for patients worldwide."

Asthma, a chronic pulmonary disease that makes breathing difficult due to inflammation or blockage of the airway, affects more than 22 million Americans and is a major cause of hospitalization in children. Worldwide, there are approximately 150 million asthmatics.

About ZaBeCor

ZaBeCor Pharmaceuticals is a biotechnology company focused on the development of siRNA, antisense and other molecular technologies for the treatment of asthma, allergy, arthritis, cardiovascular disease and other inflammatory disorders.

ZaBeCor Pharmaceuticals




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Urology
ADHD Autism Diabetes

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Talking with Your Doctor image Talking with Your Doctor

Talking with your doctor can sometimes be difficult. Good health care, however, depends on an open dialogue between patients and doctors...

Keeping a Personal Medical Record image Keeping a Personal Medical Record

Medical information is usually scattered in many different places. To receive the best possible health care, people are encouraged to gather information in one place and create a personal medical record...

View more videos...